Acute Kidney Injury (AKI), also known as acute renal failure (ARF), is a sudden episode of kidney failure or kidney damage. AKI is characterized by abrupt deterioration in kidney function, manifested by an increase in serum creatinine level with or without reduced urine output.
DelveInsight’s, “Acute Kidney Injury Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Acute Kidney Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To know more Acute Kidney Injury pipeline report offerings, click here: Acute Kidney Injury Pipeline Insight
Key Takeaways from the Acute Kidney Injury Pipeline Report
Request a sample and discover the recent breakthroughs happening Acute Kidney Injury pipeline landscape in @ Acute Kidney Injury Pipeline Outlook
A snapshot of the Acute Kidney Injury Pipeline Drugs mentioned in the report:
Drugs
Company
Phase
MoA
RoA
ANG-3777
Angion Biomedica/Vifor Pharma
Phase II
Proto oncogene protein c met stimulant
Intravenous
Ilofotase alfa
AM Pharma
Phase III
Endotoxin inhibitors; Enzyme replacements
NA
ASP1128
Astellas Pharma
Peroxisome proliferator-activated receptor delta modulators
Ruconest (Conestat alfa)
Pharming Technologies
Complement C1 inhibitor protein replacements; Complement C1r inhibitors; Complement C1s inhibitors
RMC-035
Guard Therapeutics
Alpha 1 microglobulin replacements
SBI-101
Sentien Biotechnologies
Phase I/II
Stem cell modulators
Parenteral
Timbetasin
RegeneRx Biopharmaceuticals
Preclinical
Actin modulators; Amyloid inhibitors
Learn more about the novel and emerging Acute Kidney Injury pipeline therapies @ Acute Kidney Injury Clinical Trials
DelveInsight’s Acute Kidney Injury report covers around 40+ products under different phases of clinical development like:
Request for free Sample Report to get detailed information about the recent developments in Acute Kidney Injury treatment landscape: Acute Kidney Injury Treatment and Medication
Scope of the Acute Kidney Injury Pipeline Report
To know more about the latest FDA approvals of Acute Kidney Injury drugs, click here: Acute Kidney Injury therapies and drugs
Table of Contents:
Introduction
Executive Summary
Acute Kidney Injury: Overview
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
Acute Kidney Injury – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Acute Kidney Injury Collaboration Deals
Late Stage Products (Phase III)
Teprasiran: Quark-Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
EH 301: Elysium Health
Early Stage Products (Phase I)
Centhaquine: Pharmazz
Preclinical/Discovery Stage Products
Timbetasin: RegeneRx Biopharmaceuticals
Inactive Products
Acute Kidney Injury Key Companies
Acute Kidney Injury Key Products
Acute Kidney Injury- Unmet Needs
Acute Kidney Injury- Market Drivers and Barriers
Acute Kidney Injury- Future Perspectives and Conclusion
Acute Kidney Injury Analyst Views
Appendix
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting